vTv Therapeutics (NASDAQ:VTVT) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of vTv Therapeutics (NASDAQ:VTVT) from a strong sell rating to a hold rating in a research note published on Monday,Zacks reports.

VTVT has been the subject of several other research reports. HC Wainwright cut their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Rodman & Renshaw began coverage on vTv Therapeutics in a research report on Tuesday, June 30th. They set a “buy” rating and a $67.00 price objective for the company. Lifesci Capital raised vTv Therapeutics to a “strong-buy” rating in a report on Wednesday, September 2nd. Weiss Ratings downgraded vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, BTIG Research upped their price target on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, vTv Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.83.

vTv Therapeutics Stock Down 1.7%

Shares of vTv Therapeutics stock opened at $32.79 on Monday. vTv Therapeutics has a twelve month low of $18.77 and a twelve month high of $44.00. The company’s 50 day moving average is $32.86 and its 200 day moving average is $34.51. The company has a market cap of $129.19 million, a price-to-earnings ratio of -30.93 and a beta of 0.29.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). Sell-side analysts expect that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Trading of vTv Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VTVT. Geode Capital Management LLC raised its position in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of vTv Therapeutics during the 4th quarter valued at $221,000. Finally, 683 Capital Management LLC bought a new position in vTv Therapeutics in the 4th quarter worth $731,000. 17.51% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.